{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:57:00Z","timestamp":1777078620366,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.coph.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:34:10Z","timestamp":1637541250000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-239X","authenticated-orcid":false,"given":"Chiranjib","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manojit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-6755","authenticated-orcid":false,"given":"Ashish Ranjan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.11.006_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.2020.27124","article-title":"Genetic variants of SARS-CoV-2\u2014what do they mean?","volume":"325","author":"Lauring","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2021.11.006_sref2","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01140-21","article-title":"Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants","volume":"12","author":"Chakraborty","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.coph.2021.11.006_bib3","article-title":"Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity","author":"Chakraborty","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coph.2021.11.006_bib4","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)","author":"Aleem","year":"2021"},{"key":"10.1016\/j.coph.2021.11.006_sref5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coph.2021.11.006_bib6","first-page":"1","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","author":"Tao","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coph.2021.11.006_sref7","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.3389\/fphar.2021.704205","article-title":"The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2021.11.006_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17512433.2021.1874348","article-title":"SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development","volume":"14","author":"Chakraborty","year":"2021","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.coph.2021.11.006_bib9","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms21165707","article-title":"SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells","volume":"21","author":"Cannalire","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2021.11.006_bib10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jmv.25736","article-title":"Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach","volume":"92","author":"Bhattacharya","year":"2020","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.coph.2021.11.006_bib11","doi-asserted-by":"crossref","first-page":"100394","DOI":"10.1016\/j.imu.2020.100394","article-title":"A\u00a0SARS-CoV-2 vaccine candidate: in-silico cloning and validation","volume":"20","author":"Bhattacharya","year":"2020","journal-title":"Info Med Unlock"},{"key":"10.1016\/j.coph.2021.11.006_bib12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41551-020-00660-2","article-title":"Neutralizing antibodies for the treatment of COVID-19","volume":"4","author":"Jiang","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.coph.2021.11.006_bib13","first-page":"1","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2021.11.006_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.11.006_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A\u00a0human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A\u00a0noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.11.006_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2021.11.006_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A\u00a0highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.11.006_sref20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.11.006_bib22","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.coph.2021.11.006_bib23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.coph.2021.11.006_bib24","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2021.11.006_bib25","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.coph.2021.11.006_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2021.11.006_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2021.11.006_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib29","doi-asserted-by":"crossref","first-page":"167177","DOI":"10.1016\/j.jmb.2021.167177","article-title":"Tetravalent SARS-CoV-2 neutralizing antibodies show enhanced potency and resistance to escape mutations","volume":"433","author":"Miersch","year":"2021","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.coph.2021.11.006_bib30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.coph.2021.11.006_bib31","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19\u2014final report.[published online october 8, 2020]","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.11.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2021.11.006_bib33","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.coph.2021.11.006_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.coph.2021.11.006_sref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.coph.2021.11.006_sref36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/microorganisms9051094","article-title":"Global genomic analysis of SARS-CoV-2 RNA dependent RNA polymerase evolution and antiviral drug resistance","volume":"9","author":"Mari","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.coph.2021.11.006_bib37","doi-asserted-by":"crossref","first-page":"101992","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"Iscience"},{"key":"10.1016\/j.coph.2021.11.006_bib38","doi-asserted-by":"crossref","first-page":"105033","DOI":"10.1016\/j.antiviral.2021.105033","article-title":"Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir","volume":"188","author":"Martin","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.coph.2021.11.006_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In\u00a0vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coph.2021.11.006_bib40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/pathogens9050324","article-title":"Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment","volume":"9","author":"Koyama","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.coph.2021.11.006_sref41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In\u00a0vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coph.2021.11.006_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.omtn.2021.07.011","article-title":"D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: is it part of the positive selection pioneered by Darwin?","volume":"26","author":"Chakraborty","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.coph.2021.11.006_bib43","doi-asserted-by":"crossref","first-page":"n359","DOI":"10.1136\/bmj.n359","article-title":"Covid-19: the E484K mutation and the risks it poses","volume":"372","author":"Wise","year":"2021","journal-title":"Brit Med J Pub Group"},{"key":"10.1016\/j.coph.2021.11.006_sref44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.omtn.2021.07.011","article-title":"D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: is it part of the positive selection pioneered by Darwin?","volume":"26","author":"Chakraborty","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.coph.2021.11.006_bib45","doi-asserted-by":"crossref","first-page":"198345","DOI":"10.1016\/j.virusres.2021.198345","article-title":"Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil","volume":"296","author":"da Silva Francisco","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.coph.2021.11.006_bib46","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3201\/eid2710.211189","article-title":"Genomic sequencing of SARS-CoV-2 E484K variant B. 1.243. 1, Arizona, USA","volume":"27","author":"Skidmore","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coph.2021.11.006_bib47","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coph.2021.11.006_bib48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib49","first-page":"102428","article-title":"SARS-CoV-2 Brazil variant in Latin America: more serious research urgently needed on public health and vaccine protection","volume":"66","author":"Chakraborty","year":"2021","journal-title":"Annal Med Surg"},{"key":"10.1016\/j.coph.2021.11.006_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2021.11.006_bib51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.11.006_bib52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.coph.2021.11.006_bib54","volume":"10","author":"Oplinger","year":"2020","journal-title":"Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling. National Institutes of Health"},{"key":"10.1016\/j.coph.2021.11.006_bib55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.11.006_bib56","series-title":"ClinicalTrials.gov","article-title":"Tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19","year":"2020"},{"key":"10.1016\/j.coph.2021.11.006_bib57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A\u00a0neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.11.006_bib58","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2021.11.006_bib59","series-title":"VIR-7831 for the early treatment of COVID-19 in outpatients (COMET-ICE)","author":"Vir Biotechnology","year":"2020"},{"key":"10.1016\/j.coph.2021.11.006_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2021.11.006_bib61","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coph.2021.11.006_bib62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:38Z","timestamp":1761461738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":62,"alternative-id":["S1471489221001661"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.11.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}